<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18548">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02865434</url>
  </required_header>
  <id_info>
    <org_study_id>NAV3-21</org_study_id>
    <nct_id>NCT02865434</nct_id>
  </id_info>
  <brief_title>An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous (IV) Injection and Skeletal Joint Imaging With SPECT in Subjects With Active Rheumatoid Arthritis (RA) and Healthy Controls</brief_title>
  <official_title>An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous (IV) Injection and Skeletal Joint Imaging With SPECT in Subjects With Active Rheumatoid Arthritis (RA) and Healthy Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Navidea Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Navidea Biopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, open-label, multicenter, dose escalation, safety study of injected Tc 99m
      tilmanocept in the detection of and assessment of localization to skeletal joints in
      subjects with and without active RA by SPECT imaging.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, open-label, multicenter, dose escalation, safety study of injected Tc 99m
      tilmanocept in the detection of and assessment of localization to skeletal joints in
      subjects with and without active RA by SPECT imaging. All subjects will receive IV
      administration at one of 3 mass doses: 50 µg, 200 µg, or 400 µg. Within each mass dose
      group, subjects will receive Tc 99m tilmanocept labeled with one of 3 radiolabel doses: 1
      mCi, 5 mCi, or 10 mCi.

      All subjects will have a whole body planar SPECT scan followed by a 3D SPECT or SPECT/CT
      scan on areas of interest at three specified time points: 30 minutes ± 5 minutes, 90 minutes
      ± 5 minutes and 180 minutes ± 5 minutes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicities</measure>
    <time_frame>7 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Per subject localization rate of Tc 99m tilmanocept by SPECT imaging</measure>
    <time_frame>1 Day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tc 99m tilmanocept joint localization rate in rheumatoid arthritis identified joints</measure>
    <time_frame>1 Day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concordance (proportion of joints that are identified by Tc 99m localization and clinically identified as involved with rheumatoid arthritis divided by the number of joints clinically identified as involved with rheumatoid arthritis</measure>
    <time_frame>1 Day</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Arm 1 Tc99m Tilmanocept 10 mCi 50 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1 Tilmanocept 10 mCi 50 ug in subjects diagnosed with rheumatoid arthritis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 Tc99m Tilmanocept 10 mCi 200 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 2 Tilmanocept 10 mCi 200 ug in subjects diagnosed with rheumatoid arthritis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 Tc99m Tilmanocept 10 mCi 400 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 3 Tilmanocept 10 mCi 400 ug in subjects diagnosed with rheumatoid arthritis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4 Tc99m Tilmanocept 5 mCi 50 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 4 Tilmanocept 5 mCi 50 ug in subjects diagnosed with rheumatoid arthritis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5 Tc99m Tilmanocept 5 mCi 200 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 5 Tilmanocept 5 mCi 200 ug in subjects diagnosed with rheumatoid arthritis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6 Tc99m Tilmanocept 5 mCi 400 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 6 Tilmanocept 5 mCi 400 ug in subjects diagnosed with rheumatoid arthritis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 7 Tc99m Tilmanocept 1 mCi 50 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 7 Tilmanocept 1 mCi 50 ug in subjects diagnosed with rheumatoid arthritis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 8 Tc99m Tilmanocept 1 mCi 200 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 8 Tilmanocept 1 mCi 200 ug in subjects diagnosed with rheumatoid arthritis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 9 Tc99m Tilmanocept 1 mCi 400 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 9 Tilmanocept 1 mCi 400 ug in subjects diagnosed with rheumatoid arthritis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 10 Tc99m Tilmanocept TBD mCi TBD ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 10 Tilmanocept TBD mCi TBD ug in healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tc99m tilmanocept</intervention_name>
    <arm_group_label>Arm 1 Tc99m Tilmanocept 10 mCi 50 ug</arm_group_label>
    <arm_group_label>Arm 2 Tc99m Tilmanocept 10 mCi 200 ug</arm_group_label>
    <arm_group_label>Arm 3 Tc99m Tilmanocept 10 mCi 400 ug</arm_group_label>
    <arm_group_label>Arm 4 Tc99m Tilmanocept 5 mCi 50 ug</arm_group_label>
    <arm_group_label>Arm 5 Tc99m Tilmanocept 5 mCi 200 ug</arm_group_label>
    <arm_group_label>Arm 6 Tc99m Tilmanocept 5 mCi 400 ug</arm_group_label>
    <arm_group_label>Arm 7 Tc99m Tilmanocept 1 mCi 50 ug</arm_group_label>
    <arm_group_label>Arm 8 Tc99m Tilmanocept 1 mCi 200 ug</arm_group_label>
    <arm_group_label>Arm 9 Tc99m Tilmanocept 1 mCi 400 ug</arm_group_label>
    <arm_group_label>Arm 10 Tc99m Tilmanocept TBD mCi TBD ug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>30 Minutes post-injection whole body planar SPECT imaging with 3D SPECT or SPECT/CT for targeted joints of interest</intervention_name>
    <arm_group_label>Arm 1 Tc99m Tilmanocept 10 mCi 50 ug</arm_group_label>
    <arm_group_label>Arm 2 Tc99m Tilmanocept 10 mCi 200 ug</arm_group_label>
    <arm_group_label>Arm 3 Tc99m Tilmanocept 10 mCi 400 ug</arm_group_label>
    <arm_group_label>Arm 4 Tc99m Tilmanocept 5 mCi 50 ug</arm_group_label>
    <arm_group_label>Arm 5 Tc99m Tilmanocept 5 mCi 200 ug</arm_group_label>
    <arm_group_label>Arm 6 Tc99m Tilmanocept 5 mCi 400 ug</arm_group_label>
    <arm_group_label>Arm 7 Tc99m Tilmanocept 1 mCi 50 ug</arm_group_label>
    <arm_group_label>Arm 8 Tc99m Tilmanocept 1 mCi 200 ug</arm_group_label>
    <arm_group_label>Arm 9 Tc99m Tilmanocept 1 mCi 400 ug</arm_group_label>
    <arm_group_label>Arm 10 Tc99m Tilmanocept TBD mCi TBD ug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>90 Minutes post-injection whole body planar SPECT imaging with 3D SPECT or SPECT/CT for targeted joints of interest</intervention_name>
    <arm_group_label>Arm 1 Tc99m Tilmanocept 10 mCi 50 ug</arm_group_label>
    <arm_group_label>Arm 2 Tc99m Tilmanocept 10 mCi 200 ug</arm_group_label>
    <arm_group_label>Arm 3 Tc99m Tilmanocept 10 mCi 400 ug</arm_group_label>
    <arm_group_label>Arm 4 Tc99m Tilmanocept 5 mCi 50 ug</arm_group_label>
    <arm_group_label>Arm 5 Tc99m Tilmanocept 5 mCi 200 ug</arm_group_label>
    <arm_group_label>Arm 6 Tc99m Tilmanocept 5 mCi 400 ug</arm_group_label>
    <arm_group_label>Arm 7 Tc99m Tilmanocept 1 mCi 50 ug</arm_group_label>
    <arm_group_label>Arm 8 Tc99m Tilmanocept 1 mCi 200 ug</arm_group_label>
    <arm_group_label>Arm 9 Tc99m Tilmanocept 1 mCi 400 ug</arm_group_label>
    <arm_group_label>Arm 10 Tc99m Tilmanocept TBD mCi TBD ug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>180 Minutes post-injection whole body planar SPECT imaging with 3D SPECT or SPECT/CT for targeted joints of interest</intervention_name>
    <arm_group_label>Arm 1 Tc99m Tilmanocept 10 mCi 50 ug</arm_group_label>
    <arm_group_label>Arm 2 Tc99m Tilmanocept 10 mCi 200 ug</arm_group_label>
    <arm_group_label>Arm 3 Tc99m Tilmanocept 10 mCi 400 ug</arm_group_label>
    <arm_group_label>Arm 4 Tc99m Tilmanocept 5 mCi 50 ug</arm_group_label>
    <arm_group_label>Arm 5 Tc99m Tilmanocept 5 mCi 200 ug</arm_group_label>
    <arm_group_label>Arm 6 Tc99m Tilmanocept 5 mCi 400 ug</arm_group_label>
    <arm_group_label>Arm 7 Tc99m Tilmanocept 1 mCi 50 ug</arm_group_label>
    <arm_group_label>Arm 8 Tc99m Tilmanocept 1 mCi 200 ug</arm_group_label>
    <arm_group_label>Arm 9 Tc99m Tilmanocept 1 mCi 400 ug</arm_group_label>
    <arm_group_label>Arm 10 Tc99m Tilmanocept TBD mCi TBD ug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        ALL SUBJECTS:

          -  The subject has provided written informed consent with HIPAA (Health Information
             Portability and Accountability Act) authorization before the initiation of any
             study-related procedures.

          -  Has a negative urine drug screening for illicit or unprescribed drugs suggestive of
             drug abuse.

        CONTROL SUBJECTS:

          -  The subjects shall be 30 - 65 years of age at the time of consent.

          -  The subject is deemed to be clinically free of any inflammatory disease (s) and has
             not experienced joint pain for at least 4 weeks prior to the consent date.

        ACTIVE RHEUMATOID ARTHRITIS SUBJECTS:

          -  The subject is 30 - 65 years of age at the time of consent.

          -  The subject has moderate to severe RA as determined by the 2010 ACR/EULAR (score of ≥
             6/10).

          -  The subject has a DAS28 of &gt;4.4 (includes the Erythrocyte Sedimentation Rate [ESR]
             test and Visual Analog Scale [VAS]) .

          -  If the subject is receiving methotrexate, they have been at a stable dose for &gt; 4
             weeks prior to the Baseline Visit 2 (Day 1).

          -  If the subject is receiving biologic therapy, they have been at a stable dose &gt; 8
             weeks prior to the Baseline Visit 2 (Day 1).

          -  If the subject is receiving NSAIDS or oral corticosteroids, the dose has been at a
             stable dose for &gt; 4 weeks prior to the Baseline Visit 2 (Day 1). The corticosteroid
             dose should be ≤ 10mg/day of prednisone or an equivalent steroid dose.

        Exclusion Criteria:

          -  The subject is pregnant or lactating.

          -  The subject has received any radiopharmaceutical within 7 days prior to the
             administration of Tc 99m tilmanocept. The subject is pregnant or lactating.

          -  The subject has a BMI &gt; 34.0.

          -  The subject has had or is currently receiving radiation therapy or chemotherapy for a
             condition other than rheumatoid arthritis.

          -  The subject has renal insufficiency as demonstrated by serum creatinine clearance of
             &lt; 60 mL/min.

          -  The subject has hepatic insufficiency as demonstrated by ALT or AST greater than two
             times the upper limit of normal.

          -  The subject has a chronic or persistent infection or has any condition that would, in
             the opinion of the examining physician, preclude their participation.

          -  The subject has a known allergy to or has had an adverse reaction to dextran
             exposure.

          -  The subject has received an investigational product within 30 days prior to the Tc
             99m tilmanocept administration.

          -  The subject has received any radiopharmaceutical within 7 days prior to the
             administration of Tc 99m tilmanocept.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Micheal Blue, MD</last_name>
    <role>Study Director</role>
    <affiliation>Navidea Biopharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joanna Shuping</last_name>
    <phone>614-822-2388</phone>
    <email>jshuping@navidea.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bonnie Abbruzzese</last_name>
    <phone>614-822-2327</phone>
    <email>babbruzzese@navidea.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kettering Medical Center</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Connolly, PhD</last_name>
      <phone>937-395-8227</phone>
      <phone_ext>58227</phone_ext>
      <email>Mary.Connolly@ketteringhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Allison Strefthau</last_name>
      <phone>937-395-8367</phone>
      <phone_ext>58367</phone_ext>
      <email>Allison.Streifthau@ketteringhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Arash Kardan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 13, 2017</lastchanged_date>
  <firstreceived_date>August 5, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
